ISRCTN86287193进行中（未招募）未知
Extended follow up of the TARGIT-A trial
niversity College London0 个研究点目标入组 3,451 人开始时间: 2018年4月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 3,451
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- Female
入选标准
- •1. All patients who participated in the TARGIT-A trial
- •3. 45 years and older
排除标准
- •1. Any patient who has withdrawn consent for further follow-up, or died
- •2. Any patient who is unable to give formal written consent
研究者
相似试验
进行中（未招募）
1 期
ong-Term Follow-Up Clinical Trial of Subjects Treated with PRAME TCR modified T cells, MDG1011High Risk Myeloid and Lymphoid NeopolasmsMedDRA version: 20.0 Level: PT Classification code 10061240 Term: Malignant lymphoid neoplasm System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10000886 Term: Acute myeloid leukemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: HLT Classification code 10028536 Term: Myelodysplastic syndromes System Organ Class: 100000004851MedDRA version: 16.1 Level: HLT Classification code 10028229 Term: Multiple myelomas System Organ Class: 100000004851MedDRA version: 20.0 Level: LLT Classification code 10028557 Term: Myeloid leukemia, acute System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10028533 Term: Myelodysplastic syndrome System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000717-20-DEMedigene AG52
进行中（未招募）
1 期
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of TolvaptaEuvolemic or Hypervolemic HyponatremiaMedDRA version: 19.1Level: LLTClassification code 10021038Term: HyponatremiaSystem Organ Class: 100000004861EUCTR2013-002810-11-CZOtsuka Pharmaceutical Development & Commercialization, Inc.38
进行中（未招募）
1 期
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of TolvaptaEuvolemic or Hypervolemic HyponatremiaMedDRA version: 17.1 Level: LLT Classification code 10021038 Term: Hyponatremia System Organ Class: 100000004861EUCTR2013-002810-11-ITOtsuka Pharmaceutical Development & Commercialization, Inc.140
进行中（未招募）
1 期
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of TolvaptaEUCTR2013-002810-11-DEOtsuka Pharmaceutical Development & Commercialization, Inc.140
进行中（未招募）
1 期
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of TolvaptaEUCTR2013-002810-11-ESOtsuka Pharmaceutical Development & Commercialization, Inc.140